Scribe Therapeutics has achieved a second success
Author: Michael
UK Biobank study connects gray matter difference
Endurance Bio ready for Phase 2 trials of drug t
Buck Institute perspective argues for longitudin
Serotonin Anti-Aging Centers has awarded a five-l
Edelman’s ‘100-year life’ report suggests
The global oligonucleotide therapeutics market is
Harness Therapeutics has nominated HRN001 as a fi
Wellbeing International Foundation backs cell-fr
Sana’s early diabetes data suggest hypoimmune